Joint Programming in Neurodegenerative Disease Research (JPND)

Coordinating approaches to research across the globe

Overcoming barriers

- Fragmented Research
- Non-concerted National Funding
- Duplication
- Shared research exists via EC (< 5% of total EU budget)
What is Joint Programming?

Joint programming was originally created as a Member States-led initiative in Europe. It aims to address “grand challenges” to EU and global society by coordinating national research programmes to increase the impact and effectiveness of research efforts.

Source: Communication from the Commission to the European Parliament, the Council, the European Economic and social committee and the Committee of the Regions toward Joint Programming in Research: Working together to tackle common challenges more effectively - COM(2008) 468 final, Brussels

Major societal “Grand Challenges”

- Energy
- Climate Change
- Food & Health
- Neurodegeneration
Joint Programming - a definition

Three pillars:

- **Shared vision**: JPND countries engage voluntarily and on a variable-geometry basis to tackle the major societal challenge of neurodegenerative diseases

- **Reactive management structure**: to address as efficiently as possible this societal challenge

- **Common strategic research and innovation agenda**: developed and implemented by all JPND countries

JPND brings together

- Researchers (Basic, Clinical, Healthcare/Social)
- National Funding Bodies
- National Research Strategies and Investments
- Industry
What are the goals of JPND?

To tackle the challenge of Alzheimer’s and other neurodegenerative diseases, the goals of the JPND Research Strategy are:

- To develop new treatments and preventive strategies
- To improve health and social care approaches
- To raise awareness and de-stigmatise neurodegenerative disorders
- To alleviate the economic and social burden of these diseases

A European Research Area and beyond

We cannot tackle neurodegenerative diseases by acting as single countries

JPND is the largest global ND research initiative led by EU countries, with 30 participating EU member states
Associated countries
Third countries
Increasing coordination of national research programmes to improve impact and effectiveness
Scope of the JPND initiative

- **Disease areas that the JPND Scientific Advisory Board has included:**
  - Alzheimer's disease and other dementias
  - Huntington's disease
  - Motor Neurone Diseases
  - Parkinson's disease and PD-related disorders
  - Prion disease
  - Spinal muscular atrophy (SMA)
  - Spinocerebellar ataxia (SCA)

- **Disease areas that the JPND Scientific Advisory Board have excluded:**
  - Multiple sclerosis
  - Age-related macular degeneration
  - Conditions where the primary lesion is not neurodegenerative
  - Loss of function or cell death due directly to cancer, oedema, haemorrhage, trauma, poisoning and hypoxia
  - Comorbid conditions

---

Focus on Three Domains

- **Scientific**
  - Animal models
  - Biobanks
  - Cohorts/registries
  - Disease pathology

- **Medical**
  - Early diagnosis
  - Prevention
  - Clinical trials

- **Social**
  - Health care delivery
  - Home automation
  - Health economics
  - Ethics
**Organisation**

**Management Board**
- 30 countries represented
- Members mandated to act
- Chair Philippe Amouyel - France

**Executive Board**
- Vice-Chair Adriana Maggi - Italy
- Robin Buckle – UK
- Marlies Dorlochter - Germany
- Mogens Horder - Denmark

**Steering Committee**
- Executive Board +
  - Catherine Moody – UK
  - Abida Durrani – Netherlands
  - Thomas Becker – Germany
  - Grace Kiser – France

**Scientific Advisory Board**
- 15 Members, chosen for scientific excellence and competence
- Chair Thomas Gasser - Germany

JPND partly supported by FP7-JUMPAHEAD / H2020 JPco-fuND / JP sustainD

---

**Defragmentation**
– what JPND is all about…

**STRATEGIC RESEARCH AGENDA**

**ALIGNMENT OF EU COUNTRIES ON COMMON RESEARCH GOALS**
**JPND progress to date**

- Common European Strategy
- Phase I Implementation (2012-2014)
  - Transnational Calls
  - Alignment Actions
- Phase II Implementation (2015-2020)
  - National Plans and Strategies
  - Communication + Dissemination

**SRA Implementation**

**Annual Calls for Proposals**

<table>
<thead>
<tr>
<th>Year</th>
<th>Total fund</th>
<th>Research Area</th>
<th>No. of Projects</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011</td>
<td>€16M</td>
<td>Optimization of biomarkers + harmonization of their use</td>
<td>4</td>
</tr>
<tr>
<td>2012</td>
<td>€18M</td>
<td>Risk and Protective Factors</td>
<td>5</td>
</tr>
<tr>
<td>2012</td>
<td>€11M</td>
<td>Evaluation of Healthcare</td>
<td>6</td>
</tr>
<tr>
<td>2013</td>
<td>€12M</td>
<td>Cross-Disease Analysis</td>
<td>10</td>
</tr>
<tr>
<td>2013</td>
<td>€11M</td>
<td>Preventive Strategies</td>
<td>5</td>
</tr>
<tr>
<td>2014</td>
<td>€0.5M</td>
<td>Working Groups Cohort Studies</td>
<td>10</td>
</tr>
<tr>
<td>2015</td>
<td>€16M</td>
<td>Longitudinal Cohort Approaches; Advanced Experimental Models; Risk and Protective Factors.</td>
<td>21</td>
</tr>
<tr>
<td>2016</td>
<td>€0.6M</td>
<td>Working Groups on Harmonisation and Alignment in Brain Imaging Methods</td>
<td>10</td>
</tr>
<tr>
<td>2017</td>
<td>€23M</td>
<td>Pathway Analysis Across Neurodegenerative Diseases</td>
<td>In progress</td>
</tr>
</tbody>
</table>
Centres of Excellence in Neurodegeneration (CoEN)

<table>
<thead>
<tr>
<th>Year</th>
<th>Total fund</th>
<th>Research Area</th>
<th>No. of Projects</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011</td>
<td>€6M</td>
<td>Phase I: common resources and methodological approaches</td>
<td>8</td>
</tr>
<tr>
<td>2012-13</td>
<td>€8M</td>
<td>Phase II: “Pathfinder” projects</td>
<td>5</td>
</tr>
<tr>
<td>2015-16</td>
<td>€4.9M</td>
<td>Phase II: “Pathfinder” projects</td>
<td>11</td>
</tr>
</tbody>
</table>

JPND Alignment Actions

- Alignment of National Strategies
- Alignment of National Activities
- Longitudinal Cohorts
- Assisted Living Technologies
- Industry Partnership
- Animal and Cell Models
- Palliative Care
- Patient + Public Involvement
- Optimisation of biomarkers
Additional activities

• Research mapping
• Longitudinal cohorts portal
• Experimental models site
• Recommendations from Action Groups and community-based Working Groups to develop ideas for future activity

How can countries connect with JPND?

• Members of JPND benefit from an overview of coordinated activity between 30 countries, accessible through one entry point, as well as opportunities to shape harmonised global approaches for both research and policy.

• Engagement may include:
  • Interactions with a JPND body (e.g., Scientific Advisory Board or Management Board) to further JPND’s understanding of a country’s research strategy, strengths and resources and to identify where there may be potential for new links and knowledge sharing
  • Participation in a JPND conference
  • Scientific participation in JPND Working Groups
  • Contribution to one or more future JPND funding calls
  • Full participation and membership
Keep up to date

- Visit the JPND website:
  - http://www.jpnd.eu
- Sign up to the JPND News Feeds
- E-mail us: secretariat@jpnd.eu

@JPNDEurope